Stock Market News2 days REPL Stock Rises on FDA’s Priority Review for Melanoma Drug BLA Zacks
The FDA accepts and grants priority review to Replimune’s BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on July 22, 2025.
Bristol · Bristol-Myers Squibb (BMY)
X